peptideInjectableNot FDA-approvedResearch chemicalNo published human trials; findings are limited to rodent, cell-culture, and placental-tissue modelsCirculating GDF-11's effects on aging remain scientifically disputed, including whether levels rise or fall with age
GDF-11Benefits, Dosage & Interactions
Growth Differentiation Factor 11 (GDF-11) is a protein belonging to the transforming growth factor-beta (TGF-$\beta$) superfamily. It plays a crucial role in regulating embryonic development and tissue homeostasis in adults. Research on GDF-11 focuses on healthy aging. GDF-11 is administered by injection rather than orally.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence
Animal and in-vitro studies only, no published human RCTs.
Plasma half-life
Not established
Default unit
mcg
References & evidence
Documents the GDF-11 entry is written from. Each number matches an inline marker above.
- [1]The versatility and paradox of GDF 11Jamaiyar A, Wan W, Janota DM, Enrick MK, Chilian WM, Yin L · Pharmacology & Therapeutics · 2017 · Peer-reviewed · PMID 28223232
- [2]GDF-11 as a Potential Cardiac Pro-Angiogenic FactorKato T, Lee RT · JACC: Basic to Translational Science · 2023 · Peer-reviewed · PMID 37426538
- [3]GDF-11 promotes human trophoblast cell invasion by increasing ID2-mediated MMP2 expressionWu Z, Fang L, Yang S, Gao Y, Wang Z, Meng Q, Dang X, Sun YP, Cheng JC · Cell Communication and Signaling · 2022 · Peer-reviewed · PMID 35705978
How to track GDF-11 doses
GDF-11 is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so GDF-11 is stored as a concentration rather than a guess. DoseRoutine converts that into mcg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mcg and the frequency. Cycled protocols get a start and end date so the history stays accurate when GDF-11 comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
Review GDF-11 alongside your logged metrics and any relevant blood work every few weeks before changing the dose, so the change is a response to data rather than to a good or bad day.
What to log each time
- Dose in mcg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
What is GDF-11 studied for?
What is GDF-11?
Growth Differentiation Factor 11 (GDF-11) is a protein belonging to the transforming growth factor-beta (TGF-$\beta$) superfamily. It plays a crucial role in regulating embryonic development and tissue homeostasis in adults. Originally identified for its role in inhibiting erythrocyte differentiation, GDF-11 gained significant attention in longevity research due to studies suggesting its involvement in reversing age-related decline in various tissues. It is endogenously produced in the body and its levels can fluctuate with age and health status. The research into GDF-11's precise functions and therapeutic potential is ongoing, with both promising findings and areas requiring further clarification.
What does the research say about GDF-11?
Tap a section to expand.
GDF-11 exerts its effects by binding to specific cell surface receptors, primarily activin type II receptors (ActRIIA/IIB) and subsequently recruiting activin receptor-like kinase (ALK) co-receptors (e.g., ALK4, ALK5, ALK7). This binding initiates an intracellular signaling cascade primarily through the Smad pathway. Upon receptor activation, Smad proteins become phosphorylated, form complexes, and translocate to the nucleus, where they regulate the transcription of target genes involved in cell growth, differentiation, and tissue repair. The precise downstream targets vary depending on the cell type and tissue context. For instance, in muscle, GDF-11 has been implicated in promoting satellite cell activation and regeneration. In the brain, it may influence neurogenesis and synaptic plasticity. The overall effect often involves reducing inflammation, improving mitochondrial function, and promoting cellular repair mechanisms. (PubChem)
Research into GDF-11 has identified several potential benefits, particularly in the context of aging and regenerative medicine. These include:
* **Cardiovascular Health:** Some studies suggest that GDF-11 may help reverse age-related cardiac hypertrophy (enlargement of the heart muscle) and improve cardiac function. (NIH ODS)
* **Muscle Regeneration:** GDF-11 has been shown to enhance the regenerative capacity of skeletal muscle in aged animals, potentially by activating muscle stem cells (satellite cells). (NIH ODS)
* **Neurogenesis and Cognitive Function:** Preclinical studies indicate that GDF-11 may promote neurogenesis (the birth of new neurons) in the hippocampus and improve cognitive function in aged mice. (NIH ODS)
* **Bone Remodeling:** There is evidence suggesting GDF-11's involvement in bone formation and remodeling processes, potentially mitigating age-related bone density loss. (PubChem)
* **Metabolic Regulation:** Some research points to GDF-11's role in glucose metabolism and insulin sensitivity, though consistency across studies varies. (PubChem)
It is important to note that much of this research is in animal models, and human data is still limited or inconclusive. The therapeutic potential of GDF-11 in humans is an active area of investigation.
The evidence for GDF-11's effects largely stems from preclinical studies, particularly in rodent models of aging. Early groundbreaking research published in *Cell* and *Science* in 2013-2014 by researchers including Amy Wagers and Richard Lee suggested that GDF-11 could reverse age-related heart and brain decline through parabiosis experiments (surgically joining older and younger mice to share circulatory systems), and direct GDF-11 injections. These studies highlighted GDF-11 as a potential 'rejuvenating factor.' (NIH ODS)
Subsequent research has yielded mixed results, with some studies corroborating the initial findings regarding muscle and cardiac regeneration, while others have reported conflicting data or even negative effects depending on the experimental context, concentration, and specific tissue. For example, some studies found that GDF-11 levels *increase* with age and that high GDF-11 might be associated with adverse outcomes in certain conditions. This has led to an ongoing scientific debate and a call for more robust and consistent research to fully delineate its exact roles and therapeutic potential. (PubChem, NIH ODS)
Despite the complexities, the initial findings continue to fuel interest in GDF-11's potential for developing anti-aging therapies. Clinical trials involving GDF-11 or related compounds are still in very early stages or are being developed for specific conditions rather than general longevity. (NIH ODS)
Given that GDF-11 research is predominantly preclinical, comprehensive data on side effects in humans is not available. In animal studies, the effects observed are highly dependent on the dose, duration, and method of administration. Potential theoretical side effects, based on its signaling pathways and physiological roles, could include:
* Unintended effects on cell proliferation or differentiation in various tissues.
* Interference with normal growth processes.
* Immune responses if administered heterologously.
* Potential for off-target effects due to its involvement in multiple biological pathways.
More research is needed to understand the safety profile of GDF-11 in humans. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
GDF-11 is not approved for human therapeutic use and its safety and efficacy in humans have not been established. Due to its potent signaling capabilities and role in development, caution is warranted. High doses or prolonged administration of GDF-11 could theoretically lead to unintended biological consequences. Its interaction with other growth factors and signaling pathways is complex, and disrupting this balance could have unforeseen effects. Individuals with existing medical conditions, particularly those involving cellular growth or differentiation disorders, should exercise extreme caution. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Specific contraindications for GDF-11 are not established for human use as it is not a clinically approved compound. However, based on its biological functions, theoretical contraindications could include:
* **Cancer or pre-cancerous conditions:** As GDF-11 can influence cell proliferation and differentiation, exogenous administration might theoretically impact tumor growth or metastases, though its role in cancer is complex and context-dependent (some studies suggest anti-tumor effects, others pro-tumor). (PubChem)
* **Pregnancy and breastfeeding:** Its role in embryonic development suggests it could interfere with fetal development. (PubChem)
* **Pediatric population:** Due to its role in growth and development, it would likely be contraindicated in children.
* **Autoimmune disorders:** Interference with immune regulation could be a concern.
These are theoretical considerations based on current scientific understanding and not clinical contraindications. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Given the lack of human clinical data, there is no established information on compounds that should not be mixed with GDF-11. However, due to its involvement in the TGF-$\beta$ signaling pathway, theoretically, it could interact with compounds that modulate this pathway or other growth factor signaling cascades. This includes other peptides, growth factors, or medications that affect cell growth, differentiation, or immune responses. Extreme caution should be exercised. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
There is no established clinical dosage or timing regimen for GDF-11 in humans, as it is not an approved therapeutic. In research settings, administration routes are typically injectable, and dosage and timing are user-directed and would need to be set by a licensed clinician or researcher within the confines of an approved study protocol. The half-life of GDF-11 is estimated to be approximately 1 hour, which would necessitate frequent administration if therapeutic effects were to be sustained. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
What interacts with GDF-11?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about GDF-11
GDF-11 is a protein belonging to the transforming growth factor-beta (TGF-$\beta$) superfamily, which includes many growth factors and cytokines. While it has systemic effects similar to some hormones, it is generally classified as a growth differentiation factor, regulating cell growth, differentiation, and tissue repair.
No, GDF-11 is not approved by any regulatory body (such as the FDA or EMA) for human therapeutic use. Research is ongoing, primarily in preclinical settings.
GDF-11 is a peptide and would likely be degraded by digestive enzymes if taken orally, rendering it ineffective. In research, it is typically administered via injection.
The exact factors that consistently and safely increase endogenous GDF-11 levels are not fully understood. Some lifestyle interventions such as exercise might influence growth factor levels, but a direct and significant impact on GDF-11 specifically for anti-aging purposes is not definitively proven.
GDF-11 is a peptide, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers GDF-11 with no sign-up.
GDF-11 is administered by injection, so the measured volume — not a tablet count — is the unit that matters. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a peptide like GDF-11 with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against GDF-11: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for GDF-11 varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of GDF-11 depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like GDF-11 the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Verify at
Publisher search links for GDF-11. These are places to check the information — they are not citations, so they are not numbered.
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- PubChem(publisher search, opens in a new tab)National Center for Biotechnology Information · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on GDF-11?
Plain-text summary, safe to quote verbatim:
Growth Differentiation Factor 11 (GDF-11) is a protein belonging to the transforming growth factor-beta (TGF-$\beta$) superfamily. It plays a crucial role in regulating embryonic development and tissue homeostasis in adults. Research on GDF-11 focuses on healthy aging. GDF-11 is administered by injection rather than orally.
Source: DoseRoutine — https://doseroutine.com/library/gdf-11
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). GDF-11 — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/gdf-11
What compounds are similar to GDF-11?
Others in the peptide category or studied for the same goals.
Which goals is GDF-11 used for?
Other compounds studied for the same benefits as GDF-11.
Continue exploring
See every compound DoseRoutine catalogs for these goals.